Table 1.

Demographics and baseline disease characteristics

Ipilimumab (n = 57)BSC (n = 57)Total (n = 114)
Median age (range), y65 (34–86)62 (32–80)64 (32–86)
Male, n (%)36 (63.2)41 (71.9)77 (67.5)
Race, n (%)
 White24 (42.1)27 (47.4)51 (44.7)
 Asian31 (54.4)30 (52.6)61 (53.5)
 Other2 (3.6)0 (0.0)2 (1.8)
ECOG performance status, n (%)
 032 (56.1)24 (42.1)56 (49.1)
 125 (43.9)33 (57.9)58 (50.9)
Baseline tumor type, n (%)
 Gastric48 (84.2)47 (82.5)95 (83.3)
 Gastroesophageal junction9 (15.8)10 (17.5)19 (16.7)
History of Helicobacter pylori, n (%)13 (22.8)7 (12.3)20 (17.5)
Extent of disease, n (%)
 Locally advanced7 (12.3)7 (12.3)14 (12.3)
 Metastatic50 (87.7)50 (87.7)100 (87.7)
Prior responsea to first-line chemotherapy, n (%)
 CR/PR33 (57.9)33 (57.9)66 (57.9)
 SD24 (42.1)24 (42.1)48 (42.1)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aPer modified WHO criteria and as reported by the interactive voice response system.